Welcome to our dedicated page for ROCKWELL MEDICAL SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKWELL MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKWELL MEDICAL's regulatory disclosures and financial reporting.
Rockwell Medical, Inc. furnished an updated corporate presentation as a Regulation FD Disclosure. The presentation, dated August 13, 2026, is provided as Exhibit 99.1 and is incorporated by reference. The materials are furnished, not filed, so they are not subject to Section 18 liabilities and are not automatically incorporated into Securities Act or Exchange Act filings.
Rockwell Medical, Inc. reported modest top-line growth and narrower losses for the quarter and six months ended June 30, 2026. Second-quarter net sales were $17.8 million, up 11% from a year earlier, driven mainly by $1.3 million of sales to new customers in the Western U.S. and price increases to existing accounts. Gross profit rose to $3.2 million with margin improving to 18% from 16%, helped by lower manufacturing headcount and overhead.
For the first half of 2026, net sales were $35.1 million, essentially flat year over year, as growth from new and existing customers offset a $4.3 million decline in sales to DaVita and the absence of $0.3 million of prior-year license revenue. Net loss for the six months narrowed to $2.8 million from $3.0 million, and operating cash flow turned positive at $1.9 million versus a $1.6 million outflow. The company ended the quarter with $24.8 million in cash, cash equivalents and available-for-sale investments, working capital of $25.2 million, and term loans of $9.0 million outstanding under an interest-only structure through early 2027. A 1-for-10 reverse stock split became effective July 1, 2026 to regain Nasdaq minimum bid compliance; all share data are presented on a split-adjusted basis. Management states it believes current resources are sufficient to fund operations for at least 12 months while it continues cost containment and pursues additional growth and potential capital-raising options, including $13.1 million remaining under its at-the-market equity program.
Rockwell Medical, Inc. reported second quarter 2026 net sales of $17.8 million, up 11% from $16.1 million a year earlier, driven by new customers in the Western U.S. and higher purchasing from existing customers. Gross profit rose to $3.2 million, a 30% increase, and gross margin expanded to 18% from 16% as lower manufacturing costs and higher volume improved profitability.
The company recorded a net loss of $1.2 million for the quarter, improving from a $1.5 million loss a year ago and $1.6 million in the first quarter of 2026. Adjusted EBITDA was a loss of $0.2 million, similar to the prior year period, while operating cash flow turned positive at $2.1 million, lifting cash, cash equivalents and investments to $24.8 million as of June 30, 2026.
For full-year 2026, Rockwell Medical reiterates guidance of $70–$75 million in net sales, gross margin of 18%–22%, Adjusted EBITDA of $1–$2 million, and positive operating cash flow. During the quarter it signed and extended multi-year product purchase agreements with dialysis providers and completed a 1-for-10 reverse stock split, after which it regained compliance with Nasdaq’s minimum bid price requirement.
Rockwell Medical, Inc. reported that it has received notice from Nasdaq that the company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The shares maintained a closing bid of at least $1.00 from July 1, 2026 through July 15, 2026, and Nasdaq has closed the compliance matter. The company states it is now in full compliance with all Nasdaq continued listing requirements, and its common stock remains listed and traded under the ticker RMTI.
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide, focused on supporting patients with end-stage kidney disease.
Dawson Joseph H reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director Joseph H. Dawson received an equity grant and his holdings were adjusted for a reverse split. On July 1, 2026, he was granted 9,633 shares in the form of restricted stock units at no cash cost. These units vest on July 1, 2027, if he continues serving through the 2027 annual meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical completed a 1-for-10 reverse split of its common stock, and his existing shareholdings and equity awards were proportionately reduced. After giving effect to both the grant and the reverse split adjustments, Dawson beneficially owns 12,133 shares of common stock directly.
Nissenson Allen reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Allen Nissenson received a grant of 9,633 shares of Common Stock as a compensation award, recorded at a price of $0.0000 per share. These shares are in the form of restricted stock units that vest on July 1, 2027, subject to his continued service through the 2027 annual meeting.
The company also completed a 1-for-10 reverse split of its common stock effective 12:01 a.m. on July 1, 2026, which reduced the number of shares held and adjusted outstanding equity awards. After these changes and the grant, Nissenson beneficially owns 23,892 shares directly.
Lau Joan reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Joan Lau received a grant of 9,633 shares of Common Stock as a stock award, with no cash paid per share. These restricted stock units vest on July 1, 2027, subject to her continued service through the 2027 Annual Meeting. A 1-for-10 reverse split effective July 1, 2026 adjusted her holdings to 20,944 shares after the reported grant.
Radie Robert S reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. director Robert S. Radie received an award of 9,633 shares of common stock as a grant of restricted stock units, with no cash paid per share. Following this grant, he beneficially owns 23,985 shares directly.
The restricted stock units vest on July 1, 2027, subject to his continued service through the company’s 2027 annual meeting. The company also implemented a 1-for-10 reverse stock split effective July 1, 2026, and Radie’s reported shareholdings and equity awards have been adjusted to reflect this split.
COOPER JOHN G reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical director John G. Cooper received an equity award rather than buying shares on the market. On July 1, 2026, he was granted 9,633 restricted stock units of common stock at no cash cost as compensation.
The RSUs vest on July 1, 2027, subject to his continued service through the 2027 Annual Meeting. Effective at 12:01 a.m. on July 1, 2026, Rockwell Medical implemented a 1-for-10 reverse stock split, and Cooper’s equity awards and holdings were proportionally adjusted. Following these adjustments and the reported grant, he beneficially owns 23,670 shares of common stock directly.
Chole Timothy reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. granted SVP and CCO Timothy Chole 15,000 shares of Common Stock as a compensation award, recorded at $0.00 per share. These restricted stock units vest in three equal installments on the first, second and third anniversaries of July 1, 2026, contingent on his continued service.
The company effected a 1-for-10 reverse split of its common stock effective at 12:01 AM on July 1, 2026. Following the grant and split adjustment, Chole beneficially owns 27,285 shares of Rockwell Medical common stock directly.